Genemarkers, a Kalamazoo-based biotech company specializing in the application of genomic science to health care, pharmaceutical research, and consumer product development has appointed J. Michael Getz as Chief Executive Officer. Previously serving as Co-owner and Treasurer of Detroit Oxygen & Medical Equipment Company (Detroit Oxygen), Getz brings over 30 years of experience in health care administration and health care supply management to the genomic technologies and pharmacogenomic (PGX) testing provider. In his previous role at Detroit Oxygen, Mike negotiated joint venture relationships and contracts with major Michigan-based hospitals.
“We first hired Mike as a consultant, but it was clear from the get-go that he was going to help us reach the next level.” Anna Langerveld, founder of Genemarkers. “I am a PhD scientist and Mike has an MBA from the University of Michigan. It just made sense. More importantly, I founded Genemarkers on the core principles of quality, integrity, and service. It was apparent that Mike and I shared these values right away.”
“PGX testing can help ensure that you’re prescribed the right medication, what’s known as personalized or precision medicine, so that there’s less risk for adverse effects” Getz explained. “Our genomic technologies are clearly aligned with the future of the marketplace. Not surprisingly, health care systems are interested in this testing as a way to improve outcomes and control costs.”
A PGX test analyzes mutations in genes associated with drug metabolism and targeting. Health care professionals can use the test results to make informed decisions about the most safe and effective medications for an individual based on their unique genetics. “It allows us to predict how an individual will respond to a specific drug based on the presence or absence of markers in DNA,” Dr. Langerveld continued. “Nearly everyone has a genetic mutation affecting drug metabolism.”
“I’m excited about joining the Genemarkers team. It’s a great group that is truly dedicated to providing a service that can improve patient care,” Getz said.
Dr. Langerveld will continue as President and Chief Scientific Officer, overseeing the development of new testing services, including a new test to help address opioid addiction.